Active placebos versus antidepressants for depression

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2004, Pages

  Moncrieff, Joanna ^a   Wessely, Simon ^b   Hardy, Rebecca ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; IMIPRAMINE; NORTRIPTYLINE; PLACEBO;

BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG EFFICACY; EFFECT SIZE; HAMILTON DEPRESSION RATING SCALE; HOSPITAL PATIENT; HUMAN; MINNESOTA MULTIPHASIC PERSONALITY INVENTORY; MOOD CHANGE; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EPIDEMIOLOGY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); DEPRESSION; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 2942738985     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003012.pub2     Document Type: Review

References (54)

1. Daneman EA. Imipramine in office management of depressive reactions. Diseases of the Nervous System 1961;22:213-7.
2. Friedman AS, Granick S, Cohen HW, Cowitz B. Imipramine (tofranil) vs. placebo in hospitalised psychotic depressives. Journal of Psychiatric Research 1966;4(1):13-36.
3. Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. Archives of General Psychiatry 1975;32(5):619-37.
4. Hollister LE, Overall JE, Johnson M, Pennington V, Katz G, Shelton J. Controlled comparison of imipramine, amitriptyline and placebo in hospitalised depressed patients. Journal of Nervous and Mental Disease 1964;139(4):370-5.
5. Hussain Z. Drugs in depressive illness. BMJ 1970;1(707):482.
6. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Archives of General Psychiatry 1984;41(1):33-41.
7. Uhlenhuth EH, Park LC. The influence of medication (imipramine) and doctor in relieving depressed psychoneurotic outpatients. Journal of Psychiatric Research 1964;2(2):101-22.
8. Weintraub W, Aronson H. Clinical judgement in psychopharmacological research. Journal of Neuropsychiatry 1963;5(1):65-70.
9. Wilson IC, Vernon JT, Guin T, Sandifer MG. A controlled study of treatments of depression. Journal of Neuropsychiatry 1963;4:331-7.
10. Azima H, Arthurs D, Silver A, Azima F. The effect of MP-809 in depressive states: a multi-blind study. American Journal of Psychiatry 1962;119:573-74.
11. Azima H, Silver A, Arthurs D. The effects of G-33040 in depressive states: a multi-blind study. American Journal of Psychiatry 1962;119:465-6.
12. Giannini AJ, Malone DA, Giannini MC, Price WA, Loiselle RH. Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine. Journal of Clinical Pharmacology 1986;26(3):211-14.
13. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1989;37(4):589-96.
14. Max MB, Kishore Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, Dubner R. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991;45(1):3-9.
15. Abramson JH. Meta-analysis: a review of the pros and cons. Public Health Review 1990;18(1):1-47.
16. Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom November 2004;73(6):380-5.
17. Cicchetti DV, Prusoff BA. Reliability of depression and associated clinical symptoms. Archives of General Psychiatry 1983;40(9):987-90.
18. Cole J. Therapeutic efficacy of antidepressant drugs. JAMA 1964;190:448-55.
19. Davis JM. Efficacy of tranquilising and antidepressant drugs. Archives of General psychiatry 1965;13(6):552-72.
20. Donoghue J, Tylee A, Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996;313(7061):861-2.
21. Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double-blind. Archives of General Psychiatry 1969;20(3):315-20.
22. Frank JD, Gleidman LH, Imber SD, Nash EH, Stone AR. Why patients leave psychotherapy. Archives of Neurology and Psychiatry 1957;77:283-95.
23. Gillin JC, Laurellio J, Kelsoe JR, Rapaport M, Golshan S, Kenny WM, et al. No antidepressant effect of biperiden compared with placebo in depression: A double-blind 6-week clinical trial. Psychiatric Research 1995;58(2):99-105.
24. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S. A meta-analysis of antidepressant outcome under "blinder" conditions. Journal of Consulting and Clinical Psychology 1992;60(5):664-9.
25. Greenberg RP, Fisher S. Suspended judgement. Seeing through the double-masked design: a commentary. Controlled Clinical Trials 1994;15(4):244-6.
26. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. Journal of Nervous and Mental Disease 1994;182(10):547-51.
27. Guy W. ECDEU Assessments Manual for Psychopharmacology. Rockville, MD: National Institute for Mental Health, 1976.
28. Henry JA. Debits and credits in the management of depression. British Journal of Psychiatry Supplementum 1993;20:33-39.
29. Hollister LE, Overall JE, Johnson M, Katz G, Kimbell I, Honigfeld G. Evaluation of desipramine in depressive states. Journal of New Drugs 1963;3:161-6.
30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
31. Kasper S, Moises HW, Beckman H. The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria 1981;14(6):195-8.
32. Klerman GL, Cole J. Clinical pharmacology of imipramine and related compounds. International Journal of Psychiatry 1967;3(4):267-304.
33. McNair DM. Self-evaluations of antidepressants. Psychopharmacologia 1974;37(4):281-302.
34. Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10(3):126-33.
35. Moncrieff J, Cohen D. Do Antidepressants Cure or Create Abnormal Brain States?. PLoS Med 6 June 2006;3(7):e240.
36. Moncrieff J, Goldsmith L. The Psychoactive Effects of Antidepressants and their Association with Suicidality. Curr Drug Saf 2011 Mar 4.
37. Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958-1972). Archives of General Psychiatry 1974;30(5):667-74.
38. Medical Research Council. Clinical trial of the treatment of depressive illness. BMJ 1965;1:881-6.
39. Murray EJ. Measurement issues in the evaluation of psychopharmacological therapy. In: Fisher S, Greenberg RP editor(s). The limits of biological treatments for psychological distress. Hillsdale, NJ: Lawrence Erlbaum Associates, 1989:39-68.
40. Overall JE. Dimensions of manifest depression. Journal of Psychiatric Research 1962;1:239-47.
41. The Quality Assurance Project. A treatment outline for depressive disorder. Australia and New Zealand Journal of Psychiatry 1983;17:129-46.
42. Rogers SC, Clay PM. A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illness. British Journal of Psychiatry 1975;127:599-603.
43. Rush AJ, Beck AT, Kovacs M, Hollon S. Comparative effects of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognitive Research and Therapy 1977;1(1):17-37.
44. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-412.
45. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of parallel group trials in obstetrics and gynaecology. BMJ 1996;312(7033):742-4.
46. Smith A, Traganza E, Harrison G. Studies on the effectiveness of antidepressants drugs. Psychopharmacology 1969;Suppl:1-53.
47. Smith MC, Glass GV, Miller TI. Reviews of research on the effects of drug therapy on psychological disorders. In: Smith MC, Glass GV, Miller TI editor(s). The benefits of psychotherapy. Baltimore, MD: John Hopkins University Press, 1980:127-261.
48. Stata Press. Stata. Version 5. College Station, TX: Stata Press, 1997.
49. Steinbrueck SM, Maxwell SE, Howard GS. A meta-analysis of psychotherapy and drug therapy in the treatment of unipolar depression with adults. Journal of Consulting and Clinical Psychology 1983;51(6):856-63.
50. Thomson R. Side effects and placebo amplification. British Journal of Psychiatry 1982;140:64-68.
51. Toneatto T, Sellers EM. Perception of whether drug or placebo has been administered is a determinant of drinking reduction. In: Sellers EM, Naranjo CA editor(s). Novel pharmacological interventions for alcoholism. New York, NY: Springer Verlag, 1992.
52. Wechsler H, Grosser GH, Greenblatt M. Research evaluating antidepressants in hospitalised mental patients: a survey of published reports during a five year period. Journal of Nervous and Mental Disease 1965;141(2):231-9.
53. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and the "blindability" of clinical drug trials. American Journal of Psychiatry 1992;149(12):1730-61.
54. Moncrieff J, Wessely S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry 1998;172:227-31.